| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| A655964-1ml | 1ml | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $726.90 |
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Ice chest + Ice pads |
| Product Description | AHR antagonist 5, a potent and orally active aryl hydrocarbon receptor (AHR) antagonist extracted from patent WO2018195397, example 39, has an IC 50 of < 0.5 µΜ. AHR antagonist 5 significantly inhibits tumor growth combined with checkpoint inhibitor anti-PD-1. In Vivo Tumor growth inhibition is statistically significant with AHR antagonist 5 as single. AHR antagonist 5 (10 mg/kg; p.o.; every day for 3 weeks) combination with anti-PD-1 significantly inhibited tumor growth inhibition compared to the anti-PD-1 alone . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/c Mice (Mouse Colorectal Cancer Model CT26) Dosage: 10 mg/kg (combination with anti-PD-1) Administration: P.o.; every day for 3 weeks Result: Significantly inhibited tumor growth inhibition. |
| Canonical SMILES | CC(C1=C2N(N=C1)C(N[C@H]3CC(C4=CC=CC=C4N5)=C5CC3)=NC(C6=CN=CC(F)=C6)=N2)C.Cl.Cl.Cl |
|---|---|
| Molecular Weight | 550.89 |
Enter Lot Number to search for COA:
